{"id":"W2745671375","doi":"10.1200/jco.2017.35.15_suppl.3063","title":"Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAF<sup>V600</sup>-mutant metastatic melanoma (mel): Updated safety and clinical activity.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Vemurafenib; Maculopapular rash; Rash; Nausea; Internal medicine; Melanoma; Atezolizumab; CD8; Adverse effect; Oncology; Gastroenterology; Metastatic melanoma; Pharmacology; Nivolumab; Cancer; Cancer research; Immune system; Immunotherapy; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005513647,0.0002183087,0.0004191497,0.0001970593,0.0001106085,0.0003320862,0.0002426031,0.0002073708,0.001594754],"category_scores_gemma":[0.0004502379,0.0001037679,0.0004624603,0.0001940845,0.0001099346,0.0002464386,0.0001439909,0.0008525288,0.0003112416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003633179,"about_ca_system_score_gemma":0.0003398563,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000328115,"about_ca_topic_score_gemma":0.001315878,"domain_scores_codex":[0.9998635,0.00004848659,0.00001934449,0.0000186688,0.00003077921,0.00001931743],"domain_scores_gemma":[0.9997299,0.00006464517,0.0001231126,0.00001506208,0.00002268322,0.00004462203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1137183,0.005194247,0.03317736,0.002275273,0.0009808992,0.0004720471,0.0001320145,0.003547492,0.05454659,0.000463858,0.007560097,0.7779318],"study_design_scores_gemma":[0.07920568,0.5127079,0.2201872,0.001118546,0.004077028,0.01120784,0.0002388175,0.0107492,0.05810049,0.001143201,0.1011655,0.00009851978],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9632756,0.0286411,0.0009848673,0.0005531353,0.00009977942,0.0002933397,0.0009365255,0.000101104,0.005114571],"genre_scores_gemma":[0.9912635,0.005344125,0.000731223,0.0003003848,0.00006214513,0.0001045773,0.001197817,0.000009240291,0.0009869878],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001594754,"threshold_uncertainty_score":0.005334973,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08158401592202198,"score_gpt":0.4247040565933026,"score_spread":0.3431200406712806,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}